|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We report the discovery of β-catenin+ cancer cells that co-express E-cadherin and vimentin in core needle biopsies from patients with various advanced metastatic carcinomas wherein these cells are transitioning between strongly epithelial and strongly mesenchymal-like phenotypes.
|
31732654 |
2020 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
For the Ca-ex-PAs, the average positivity of C-myc was 36.4%; the average proliferation index of Ki-67 was 29.2%; pan-cytokeratin was positive in all cases, and vimentin was positive in myoepithelial carcinomas.
|
31456912 |
2019 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The immunoprofile indicated unfavorable prognosis for mesenchymal-type carcinomas (negativity for E-cadherin and positivity for vimentin, with membrane to nuclear translocation or negativity of <i>β</i>-catenin).
|
31205468 |
2019 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There were significant immunophenotypic differences between adenosquamous carcinomas and pure invasive stratified mucin-producing carcinomas with regard to HPV (p < 0.0001), PAX8 (p = 0.038; more in adenosquamous carcinoma), p40 (p < 0.0001; more in adenosquamous carcinoma), p63 (p = 0.0018; more in adenosquamous carcinoma) and MUC6 (p < 0.0001; less in adenosquamous carcinoma), HNF-1beta (p = 0.0023), vimentin (p = 0.0003), p53 (p = 0.0004), and CK7 (p = 0.0002) expression.
|
30258209 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carbonic anhydrase 9 (CA9) and vimentin are hypoxia and epithelial-mesenchymal transition-related proteins of which expression in many carcinomas has been associated with poor prognosis, but their significance in PanNET has yet to be determined.
|
29666945 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Vimentin is an intermediate filament protein, predominantly expressed in cells of mesenchymal origin, although its aberrant expression is seen in many carcinomas during epithelial mesenchymal transition.
|
28225793 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry for vimentin and cytokeratin 20 (CK20) was evaluated in carcinoid-like (n = 2), labyrinthine (n = 4), rippled (n = 3), and conventional (n = 6) sebaceomas; sebaceous mantle hyperplasia (n = 1); steatocystomas (n = 5); fibrofolliculomas (n = 4); sebaceous mantleoma (n = 1); sebaceous gland hyperplasias (n = 4); sebaceous adenomas (n = 4); and sebaceous carcinomas (n = 4) as well as normal skin tissue.
|
28027080 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Vimentin is currently used to differentiate between malignant renal carcinomas and benign oncocytomas.
|
25944973 |
2015 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Vimentin is a type III intermediate filament protein that is expressed frequently in epithelial carcinomas correlating with invasiveness and also poor prognosis of cancer.
|
24612689 |
2014 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer.
|
25249140 |
2014 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Reduced E-cadherin is a hallmark of invasive carcinomas that have acquired epithelial-mesenchymal transition (EMT) phenotypes and Vimentin is another molecule that is used widely as a marker of the EMT.
|
23504993 |
2013 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Vimentin, a mesenchymal marker, is frequently overexpressed in epithelial carcinomas undergoing epithelial to mesenchymal transition (EMT), a condition correlated with invasiveness and poor prognosis.
|
22236966 |
2012 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The methylation status of the Vimentin gene was examined in primary carcinomas and the corresponding normal tissues derived from 43 patients with hepatocellular carcinoma (HCC) using quantitative methylation-specific PCR (qMSP) and the correlation between the methylation status and the clinicopathological findings was evaluated.
|
21508377 |
2011 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Twist1 (P < 0.001), Zeb1 (P = 0.003) and Vimentin (P = 0.03) mRNA expression was significantly higher in solid metastases compared to primary carcinomas and effusions.
|
20213325 |
2010 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, a trend was shown toward advancement of gastric carcinomas with vimentin methylation (p=0.0588).
|
19528485 |
2009 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The methylation status of the Vimentin gene was examined in primary carcinomas and the corresponding normal tissues derived from 48 patients with colorectal cancer using quantitative methylation-specific PCR (qMSP) and the correlation between the methylation status and the clinicopathological findings was evaluated.
|
19331162 |
2009 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study was undertaken to show these differences comparing the immunoexpression of two clones of vimentin (V9 and Vim 3B4, DAKO, Carpenteria, CA) using 10 pleomorphic adenomas, 10 adenoid cystic carcinomas, and 4 epithelial/myoepithelial carcinomas of the salivary glands.
|
16785793 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Vimentin-expressing carcinomas revealed a significantly higher average absolute number of cytogenetic alterations per case, but a significantly lower frequency of chromosome 16q losses compared to vimentin-negative cases.
|
15906273 |
2005 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
45% of the carcinomas were positive for vimentin.
|
11326639 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of vimentin intermediate filaments (IFs), a mesenchymal marker, is typical of melanomas, whereas carcinomas typically express keratin IFs, which are markers for epithelia.
|
9484713 |
1998 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analysis of several other kinds of epithelial carcinoma cell lines showed only rare examples of vimentin expression.
|
2472876 |
1989 |